Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New molecular test aims to sharpen kidney transplant rejection diagnosis

NCT ID NCT07347353

Knowledge-focused Sponsor: Paris Translational Research Center for Organ Transplantation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether a molecular test called HistoMx can help doctors better diagnose kidney transplant rejection in everyday practice. Researchers followed 400 kidney transplant recipients to see how often the test was used and whether it improved patient outcomes. The goal was to understand the real-world value of adding this test to standard methods.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

400 people

The number who actually took part.

Started

Feb 2020

Finished

Dec 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Kidney transplant recipients from two French referral centers

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Kidney recipients older than 18 years of age * Patients receiving a kidney transplant from a living or brain-dead donor Exclusion Criteria: * Patients who have received a previous transplant with an organ other than the kidney * Patients without available graft biopsy material for molecular HistoMx testing

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Graft rejection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

transplant rejection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Graft rejection

Contacts and locations

Locations

  • Paris Bichat university hospital

    Paris, France

  • Paris Saint Louis University hospital

    Paris, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.